Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

MK-7684A avec ou sans autres traitements anticancéreux chez les participants atteints de tumeurs solides sélectionnées (MK-7684A-005) (KEYVIBE-005)

3 septembre 2026 mis à jour par: Merck Sharp & Dohme LLC

Une étude multicentrique, ouverte, de phase 2 sur panier de MK-7684A, une co-formation de vibostolimab (MK-7684) avec du pembrolizumab (MK-3475), avec ou sans autres traitements anticancéreux chez des participants atteints de tumeurs solides sélectionnées

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

611

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Berlin, Allemagne, 12203
        • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Allemagne, 69120
        • Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
      • Tübingen, Baden-Wurttemberg, Allemagne, 72076
        • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
    • Bavaria
      • München, Bavaria, Allemagne, 81337
        • Klinikum der Universität München Großhadern ( Site 1176)
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Allemagne, 40225
        • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Cancer Centre ( Site 1056)
    • Araucania
      • Temuco, Araucania, Chili, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 1404)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chili, 7500921
        • FALP-UIDO ( Site 1401)
      • Santiago, Region M. de Santiago, Chili, 7510032
        • Oncovida ( Site 1405)
      • Santiago, Region M. de Santiago, Chili, 8420383
        • Bradfordhill-Clinical Area ( Site 1402)
    • Antioquia
      • Medellín, Antioquia, Colombie, 050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
    • Atlántico
      • Barranquilla, Atlántico, Colombie, 080020
        • Clinica de la Costa S.A.S. ( Site 1421)
    • Cundinamarca
      • Bogotá, Cundinamarca, Colombie, 111511
        • Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
    • Risaralda Department
      • Pereira, Risaralda Department, Colombie, 661001
        • Oncologos del Occidente ( Site 1424)
    • Santander Department
      • Piedecuesta, Santander Department, Colombie, 681017
        • Fundación Cardiovascular de Colombia ( Site 1423)
      • Seoul, Corée du Sud, 03080
        • Seoul National University Hospital-Internal Medicine ( Site 1312)
      • Seoul, Corée du Sud, 03722
        • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)
      • Seoul, Corée du Sud, 05505
        • Asan Medical Center ( Site 1313)
      • Madrid, Espagne, 28027
        • Clinica Universidad de Navarra-Medical Oncology ( Site 1118)
      • Seville, Espagne, 41013
        • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)
    • Barcelona
      • Hospitalet, Barcelona, Espagne, 08907
        • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)
    • Madrid
      • Pozuelo de Alarcón, Madrid, Espagne, 28223
        • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espagne, 28034
        • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)
      • Paris, France, 75248
        • Institut Curie ( Site 1152)
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, France, 69373 Cedex 08
        • CENTRE LEON BERARD-Medical oncology ( Site 1151)
    • Cote-d Or
      • Dijon, Cote-d Or, France, 21079
        • Centre Georges François Leclerc ( Site 1155)
    • Herault
      • Montpellier, Herault, France, 34298
        • Institut Regional du Cancer Montpellier ( Site 1157)
    • Paris
      • Villejuif, Paris, France, 94800
        • Gustave Roussy-medicine departement ( Site 1153)
    • Vaucluse
      • Avignon, Vaucluse, France, 84000
        • Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)
      • Haifa, Israël, 3109601
        • Rambam Health Care Campus-Oncology ( Site 1141)
      • Jerusalem, Israël, 9112001
        • Hadassah Medical Center-Oncology ( Site 1142)
      • Ramat Gan, Israël, 5265601
        • Sheba Medical Center-ONCOLOGY ( Site 1144)
      • Tel Aviv, Israël, 6423906
        • Sourasky Medical Center-Oncology ( Site 1143)
      • Milan, Italie, 20141
        • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
      • Naples, Italie, 80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)
    • Lazio
      • Rome, Lazio, Italie, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)
    • Lombardy
      • Milan, Lombardy, Italie, 20132
        • Ospedale San Raffaele-Oncologia Medica ( Site 1135)
    • Milano
      • Rozzano, Milano, Italie, 20089
        • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)
      • Osaka, Japon, 541-8567
        • Osaka International Cancer Institute ( Site 1323)
      • Tokyo, Japon, 104-0045
        • National Cancer Center Hospital ( Site 1322)
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 464-8681
        • Aichi Cancer Center Hospital ( Site 1324)
    • Chiba
      • Kashiwa, Chiba, Japon, 277-8577
        • National Cancer Center Hospital East ( Site 1321)
    • North Holland
      • Amsterdam, North Holland, Pays-Bas, 1066CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)
    • South Holland
      • Rotterdam, South Holland, Pays-Bas, 3015 GD
        • Erasmus Medisch Centrum-Medical Oncology ( Site 1122)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Pologne, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Pologne, 80-952
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)
    • West Pomeranian Voivodeship
      • Koszalin, West Pomeranian Voivodeship, Pologne, 75-581
        • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)
      • Tainan, Taïwan, 704
        • NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)
      • Taipei, Taïwan, 10002
        • National Taiwan University Hospital-Oncology ( Site 1301)
      • Taipei, Taïwan, 10449
        • Mackay Memorial Hospital ( Site 1305)
      • Taoyuan, Taïwan, 333
        • Chang Gung Medical Foundation-Linkou Branch ( Site 1304)
      • Adana, Turquie (Türkiye), 01250
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)
      • Ankara, Turquie (Türkiye), 06230
        • Hacettepe Universitesi-oncology hospital ( Site 1209)
      • Ankara, Turquie (Türkiye), 06800
        • Ankara City Hospital-Medical Oncology ( Site 1202)
      • Edirne, Turquie (Türkiye), 22030
        • Trakya University-Medical Oncology ( Site 1207)
      • Istanbul, Turquie (Türkiye), 34303
        • Acibadem Universitesi Atakent Hastanesi ( Site 1208)
      • Istanbul, Turquie (Türkiye), 34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)
    • Istanbul
      • Istanbul- Fatih, Istanbul, Turquie (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa ( Site 1203)
    • Alaska
      • Anchorage, Alaska, États-Unis, 99508
        • Alaska Womens Cancer Care ( Site 1016)
    • California
      • Duarte, California, États-Unis, 91010
        • City of Hope Comprehensive Cancer Center ( Site 1001)
      • Orange, California, États-Unis, 92868-3201
        • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
    • Michigan
      • Detroit, Michigan, États-Unis, 48201
        • Karmanos Cancer Institute ( Site 1007)
    • New Jersey
      • Basking Ridge, New Jersey, États-Unis, 07920
        • Memorial Sloan Kettering - Basking Ridge ( Site 1023)
      • Middletown, New Jersey, États-Unis, 07748
        • Memorial Sloan Kettering - Monmouth ( Site 1022)
      • Montvale, New Jersey, États-Unis, 07645
        • Memorial Sloan Kettering - Bergen ( Site 1025)
    • New York
      • Commack, New York, États-Unis, 11725
        • Memorial Sloan Kettering- Commack ( Site 1021)
      • Harrison, New York, États-Unis, 10604
        • Memorial Sloan Kettering - Westchester ( Site 1020)
      • New York, New York, États-Unis, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 1002)
      • Uniondale, New York, États-Unis, 11553
        • Memorial Sloan Kettering - Nassau ( Site 1026)
    • Oklahoma
      • Tulsa, Oklahoma, États-Unis, 74146
        • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
    • South Dakota
      • Sioux Falls, South Dakota, États-Unis, 57104
        • Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Houston Methodist Hospital ( Site 1017)

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:

    • Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
    • Endometrial cancer
    • Head and neck squamous cell carcinoma (HNSCC)
    • Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
    • Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
    • Triple-negative breast cancer (TNBC)
    • Hepatocellular carcinoma (HCC)
    • Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
    • Ovarian cancer
    • Gastric cancer
  • Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.

  • Adequately controlled blood pressure (BP) with or without antihypertensive medications.

  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).

  • Male participants must agree to follow contraceptive guidance.

  • Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.

  • Adequate organ function.

Exclusion Criteria:

  • History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  • Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
  • Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Active infection requiring systemic therapy.
  • Concurrent active hepatitis B and hepatitis C virus infection.
  • History of allogenic tissue/solid organ transplant.
  • Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Pembrolizumab/Vibostolimab Co-Formulation

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Autres noms:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®
Expérimental: Pembrolizumab

Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®
Expérimental: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Autres noms:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Autres noms:
  • E7080
  • Lenvima
  • MK-7902
Expérimental: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Autres noms:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Autres noms:
  • E7080
  • Lenvima
  • MK-7902
Expérimental: Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Autres noms:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

Autres noms:
  • 5-FU
  • Fluracil

Cisplatin administered via IV infusion

Autres noms:
  • Platinol
  • platine cis
Expérimental: Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Autres noms:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

Paclitaxel administered via IV infusion at investigator's choice of dose

Autres noms:
  • Taxol
  • Abraxane
  • Anzatax
Expérimental: Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

Cisplatin administered via IV infusion

Autres noms:
  • Platinol
  • platine cis

Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

Expérimental: Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

Paclitaxel administered via IV infusion at investigator's choice of dose

Autres noms:
  • Taxol
  • Abraxane
  • Anzatax

Carboplatin administered via IV infusion at investigator's choice of dose and frequency

For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

Expérimental: Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.

Pembrolizumab 200 mg administered via IV infusion Q3W.

Autres noms:
  • MK-3475
  • KEYTRUDA®

Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Oxaliplatin administered via IV infusion Q3W up to 35 cycles

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
Délai: Up to approximately 24 months

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen & Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Délai: Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Délai: Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.

Up to approximately 24 months
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
Délai: 9 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

9 months
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
Délai: 12 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Survival (OS) in Participants With Selected Solid Tumors
Délai: Up to approximately 46 months

For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.

Up to approximately 46 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Délai: Up to approximately 46 months

PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.

Up to approximately 46 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Délai: Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.

Up to approximately 46 months
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Délai: Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.

Up to approximately 46 months
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
Délai: Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
Délai: Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
Délai: Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.

Baseline and up to Week 12
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
Délai: Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.

Baseline and up to Week 12
Number of Participants Who Experienced One or More Adverse Events (AEs)
Délai: Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.

Up to approximately 46 months
Number of Participants Who Discontinued Study Intervention Due to an AE
Délai: Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.

Up to approximately 46 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Medical Director, Merck Sharp & Dohme LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 septembre 2021

Achèvement primaire (Réel)

5 août 2025

Achèvement de l'étude (Réel)

5 août 2025

Dates d'inscription aux études

Première soumission

10 août 2021

Première soumission répondant aux critères de contrôle qualité

10 août 2021

Première publication (Réel)

16 août 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 septembre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 7684A-005
  • MK-7684A-005 (Autre identifiant: MSD)
  • jRCT2031210335 (Identificateur de registre: jRCT)
  • KEYVIBE-005 (Autre identifiant: MSD)
  • 2021-001009-56 (Numéro EudraCT)
  • U1111-1291-4290 (Identificateur de registre: UTN)
  • 2023-505284-36-00 (Identificateur de registre: EU CT)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner